Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225] Draft guidance Technology appraisal ...

Suggested remit: To appraise the clinical and cost effectiveness of iptacopan within its marketing authorisation for treating complement 3 (C3) glomerulopathy.

A list of downloadable documents created during development.

Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) TA1006 12 September 2024 12 September 2024 Evinacumab for treating homozygous familial hypercholesterolaemia ...

Suggested remit: To appraise the clinical and cost effectiveness of vutrisiran within its marketing authorisation for treating transthyretin amyloidosis with cardiomyopathy ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

A list of downloadable documents created during development.

For further information on the guideline development process, please see how we develop NICE guidelines ...

Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins. NHS England ...

A list of downloadable documents created during development.